Form 8-K Hoth Therapeutics, Inc. For: Jun 17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 17, 2021
Hoth Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Nevada | 001-38803 | 82-1553794 | ||
(State
or other jurisdiction of incorporation) |
(Commission File Number) | (I.
R. S. Employer Identification No.) |
1 Rockefeller Plaza, Suite 1039 |
New York, New York 10020 |
(Address of principal executive offices, including ZIP code) |
(646) 756-2997 |
(Registrant’s telephone number, including area code) |
Not Applicable |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common stock, $0.0001 par value | HOTH | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On June 17, 2021, Hoth Therapeutics, Inc. entered into an amendment to the Non-Exclusive Commercial Evaluation License Agreement (the “License Agreement”) with the U.S. Army Medical Research and Development Command originally executed on December 22, 2020 (the “Effective Date”) pursuant to which the term of the License Agreement was extended such that it will terminate 12 months from the Effective Date.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 18, 2021 | Hoth Therapeutics, Inc. |
/s/ Robb Knie | |
Robb Knie | |
Chief Executive Officer |
2
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Danske Bank A/S, transactions by persons discharging managerial responsibilities
- Flash News: OKX Web3 Team Announces X Spaces Event on 'Maximizing Value on the Mode Ecosystem'
- Leicester NC Diesel Performance Parts For Improved Fuel Efficiency, Range Update
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!